Last checked at 22 Jul 2022 18:00
22 July 2022
PureTech Health plc
PDMR Notifications
PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company dedicated to discovering, developing and commercializing highly differentiated medicines for devastating diseases, announces that awards of restricted share units ("RSUs") granted by PureTech on 21 July 2021 to certain non-executive directors ("PDMRs") pursuant to its Performance Share Plan ("PSP") vested in full on 15 June 2022 immediately prior to the Company's Annual General Meeting of Stockholders. Each PDMR received vested ordinary shares on 22 July 2022.
The Company's total issued ordinary share capital is 288,689,450 shares after the share issuance to the PDMRs, 3,563,665 shares of which are held in treasury by the Company.
PDMR Notification
The information contained in the below notification is disclosed in accordance with Article 19 of the EU Market Abuse Regulation.
1 | Details of the person discharging managerial responsibilities/person closely associated | ||||||||||||||||||||||
a) | Name | Raju Kucherlapati John LaMattina Robert Langer Kiran Mazumdar-Shaw Marjorie Scardino Christopher Viehbacher
| |||||||||||||||||||||
2 | Reason for the notification | ||||||||||||||||||||||
a) | Position/status | Non-Executive Directors | |||||||||||||||||||||
b) | Initial notification/Amendment | Initial Notification | |||||||||||||||||||||
3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||||||||||||||||||||
a) | Name | PureTech Health plc | |||||||||||||||||||||
b) | LEI | 213800LVPDNO2Z9T9I39 | |||||||||||||||||||||
4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||||||||||||||||||||||
a) | Description of the financial instrument, type of instrument |
| |||||||||||||||||||||
b) | Nature of the transaction | Issuance of ordinary shares in settlement of certain vested RSUs under the PureTech Health Performance Share Plan. | |||||||||||||||||||||
c) | Price(s) and volume(s) |
| |||||||||||||||||||||
d) | Aggregated information
|
| |||||||||||||||||||||
e) | Date of the transaction | 22 July 2022 | |||||||||||||||||||||
f) | Place of the transaction | London Stock Exchange (XLON) | |||||||||||||||||||||
About PureTech Health
PureTech is a clinical-stage biotherapeutics company dedicated to discovering, developing and commercializing highly differentiated medicines for devastating diseases, including inflammatory, fibrotic and immunological conditions, intractable cancers, lymphatic and gastrointestinal diseases and neurological and neuropsychological disorders, among others. The Company has created a broad and deep pipeline through the expertise of its experienced research and development team and its extensive network of scientists, clinicians and industry leaders. This pipeline, which is being advanced both internally and through PureTech's Founded Entities, is comprised of 27 therapeutics and therapeutic candidates, including two that have received both U.S. FDA clearance and European marketing authorization, as of the date of PureTech's most recently filed Annual Report and corresponding Form 6-K. All of the underlying programs and platforms that resulted in this pipeline of therapeutic candidates were initially identified or discovered and then advanced by the PureTech team through key validation points based on unique insights in immunology and drug development.
For more information, visit www.puretechhealth.com or connect with us on Twitter @puretechh.
Contact:
PureTech
Investor Relations
IR@puretechhealth.com